Prevail GLP-1 Weight Loss Program​ (Semaglutide) Month 4

WHAT IS SEMAGLUTIDE?

Semaglutide, the active ingredient in Wegovy, is an FDA-approved injectable for weight loss that mimics the actions of GLP-1, a hormone that targets specific areas of the brain known to suppress hunger. 

PROGRAM INFORMATION

The Prevail GLP-1 Weight Loss (Semaglutide) Program includes the following:

• Semaglutide Prescription
• Initial consult with a MyDietDoc physician
• Initial consult with a MyDietDoc nutrition expert
• Customized meal plan
• Monthly health webinars
• Unlimited texting with our MyDieDoc nutritionist
• Order of Zofran

HEALTH BENEFITS OF PROGRAM

Semaglutide is a glucagon-like peptide-1 agonist that promotes weight loss by controlling appetite. Losing excess weight can provide many health benefits, such as:

• Improved Cardiovascular Health
• Improved Metabolic Health
• Restoration of Hormones
• Reduced Pain
• Decreased Blood Pressure
• Decreased Risk for Cardiovascular Disease
• Better Lung Function
• Reduced Risk for Stroke or Heart Attack
• Lower Triglycerides
• Improved Mobility
• Less Joint Damage
• Lower Risk of Erectile Dysfunction
• Enhanced Libido
• Higher Self-Esteem
• Better Sleep

HOW DOES SEMAGLUTIDE WORK?

Semaglutide, the active ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) agonist used in conjunction with a reduced-calorie diet and exercise to promote sustainable weight loss. It has demonstrated more potent effects compared to other medications in its class, potentially due to its higher dosage. By binding to brain receptors that regulate hunger and appetite, semaglutide alters food preferences and reduces calorie consumption. Its mechanism of action involves delaying stomach emptying and slowing intestinal motility, leading to prolonged satiety. Additionally, GLP-1 agonists stimulate insulin secretion and decrease glucagon release, resulting in lower blood glucose levels. 

Several clinical trials evaluated semaglutide’s efficacy and safety in overweight or obese individuals, with or without diabetes. These trials incorporated behavioral interventions like counseling on diet and exercise, as well as meal replacements. The largest trial revealed that the group receiving semaglutide achieved a remarkable 12% more weight loss at 68 weeks compared to the placebo, equivalent to an average of 35 pounds. Semaglutide is particularly beneficial for individuals struggling with appetite control and snacking tendencies.

*Health consent forms, a doctor consultation, and a doctor approval are all required

*Available in all 50 states

*Filled with a 3rd party pharmacy